Avita Medical is generating sales worldwide for its innovative regenerative product portfolio. The Company operates from offices in Cambridge, UK, Northridge, California and Perth, Australia.
Our products, for the treatment of a wide range of wounds, scars and skin defects, are currently available via a direct sales force in Australia and globally through distributors in the UK, France, Germany, Austria, Switzerland, Turkey, China, Japan, Taiwan, Saudi Arabia, South Korea and the US.
Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin.
Our medical devices work by preparing a Regenerative Epithelial Suspension (RES™), an autologous suspension comprised of the patients’ own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated.
In all countries outside of Europe, our portfolio is marketed under the ReCell® brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics.
ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational and compassionate use. A pivotal U.S. trial is well underway aiming to secure FDA approval1.
In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names.
ReCell® is designed for the treatment of burns and plastic reconstructive procedures; ReGenerCell™ has been formulated for chronic wounds including leg and foot ulcers; and ReNovaCell™ is tailored for aesthetic applications including the restoration of pigmentation.